Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

GoodRx Rises Despite Weak Earnings, Forecast

Published 05/15/2021, 12:19 AM
Updated 05/15/2021, 12:19 AM
© Reuters.

© Reuters.

By Christiana Sciaudone

Investing.com -- Goodrx Holdings Inc (NASDAQ:GDRX) rose 6% despite reporting earnings and guidance that missed the mark, if by a small margin.

Earnings per share of 7 cents missed expectations by a hair while sales of $160.4 million fell just short of the $160.5 million analysts had forecast, according to data compiled by Investing.com. Revenue for the year was estimated at $740 million to $760 million, below the consensus of $784.4 million, according to StreetInsider. On the slightly more positive side, sales for the second quarter are expected at $172 million to $176 million versus the forecast of $172.4 million. 

Shares of GoodRx have slipped more than 40% since the company went public in September. The threat of Amazon (NASDAQ:AMZN) has since reared its giant head in the world of healthcare, sending shivers down the spines of investors who fear that GoodRx could take a major hit from the rivalry.

Analysts from RBC Capital to Barclays (LON:BARC) dropped the company's price target following the first quarter results.

On Thursday, Bloomberg, citing people familiar with the situation, reported that GoodRx bought discount drug company RxSaver from Vericast Corp., controlled by billionaire Ronald Perelman. 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.